Please assess the completion status of the following clinical trial:

Trial Title: Rectal Indomethacin to Prevent Post ESWL-pancreatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* any patient with chronic pancreatitis and pancreatic stones (\> 5 mm in diameter) undergoing P-ESWL~* at least 18 years old~* provides informed consent~Exclusion Criteria:~* readmitted to the hospital during the enrollment of the study~* contraindications to ESWL~* suspected or established malignancy~* pancreatic ascites~* receiving NSAIDs within 7 days~* contraindication to NSAIDs (including gastrointestinal hemorrhage within 4 weeks or renal dysfunction with serum creatinine \>120 μmol/L)~* presence of coagulopathy or received anticoagulation therapy within 3 days~* acute pancreatitis within 3 days~* known active cardiovascular or cerebrovascular disease~* pregnant or breastfeeding women~* without a rectum (ie, status post-total proctocolectomy)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Indomethacin (Type: EXPERIMENTAL): Subjects will be randomized to receive a 100-mg indomethacin suppository 30 min before ESWL.
- Glycerin (Type: PLACEBO_COMPARATOR): Subjects will be randomized to receive either a 100-mg identical-appearing placebo (glycerin suppository) 30 min before ESWL.

Based on this trial design, predict the completion outcome and termination type (if applicable).